AXGN Stock Overview
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Axogen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.80 |
52 Week High | US$15.08 |
52 Week Low | US$3.45 |
Beta | 1.13 |
11 Month Change | 8.58% |
3 Month Change | 90.61% |
1 Year Change | 172.73% |
33 Year Change | -12.66% |
5 Year Change | 15.48% |
Change since IPO | 409.23% |
Recent News & Updates
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Sep 14Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
Aug 20Recent updates
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Sep 14Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
Aug 20A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb
Jul 29Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost
Jun 12Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?
Apr 16Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump
Mar 28Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost
Jan 26We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt
Sep 10Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues
Aug 09AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?
Jan 13Is AxoGen (NASDAQ:AXGN) A Risky Investment?
Sep 10AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings
Aug 02Axogen estimates Q2 revenue above consensus, reaffirms guidance
Jul 18Shareholder Returns
AXGN | US Medical Equipment | US Market | |
---|---|---|---|
7D | -5.9% | -0.4% | 1.8% |
1Y | 172.7% | 21.1% | 31.9% |
Return vs Industry: AXGN exceeded the US Medical Equipment industry which returned 21.1% over the past year.
Return vs Market: AXGN exceeded the US Market which returned 31.9% over the past year.
Price Volatility
AXGN volatility | |
---|---|
AXGN Average Weekly Movement | 11.8% |
Medical Equipment Industry Average Movement | 8.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AXGN's share price has been volatile over the past 3 months.
Volatility Over Time: AXGN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 427 | n/a | www.axogeninc.com |
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
Axogen, Inc. Fundamentals Summary
AXGN fundamental statistics | |
---|---|
Market cap | US$622.38m |
Earnings (TTM) | -US$16.54m |
Revenue (TTM) | US$173.48m |
3.5x
P/S Ratio-36.6x
P/E RatioIs AXGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AXGN income statement (TTM) | |
---|---|
Revenue | US$173.48m |
Cost of Revenue | US$35.79m |
Gross Profit | US$137.69m |
Other Expenses | US$154.23m |
Earnings | -US$16.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.38 |
Gross Margin | 79.37% |
Net Profit Margin | -9.53% |
Debt/Equity Ratio | 51.7% |
How did AXGN perform over the long term?
See historical performance and comparison